English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12500/13673 (91%)
造訪人次 : 2631867      線上人數 : 269
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/15517


    題名: Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
    作者: Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C
    貢獻者: National Institute of Cancer Research;Institute of Population Health Sciences
    摘要: Background: This study evaluated the efficacy, safety, and surgical outcome for HCC patients who are potentially eligible for curative surgery after neoadjuvant N+I, as defined by one of the following: (a) macrovascular invasion (AJCC T3) (b) multiple (>3) or tumors in bilateral lobes (AJCC T2) (c) AJCC T2 tumors with significant portal hypertension (d) other conditions with high risk of recurrence (NCT03510871). Methods: Eligible subjects must have histological diagnosis of HCC, measurable tumors (RECIST 1.1), ECOG 0-1, Child-Pugh A. Nivolumab 3 mg/kg + ipilimumab 1 mg/kg were given every 3 weeks. Tumor assessment was done after 2 and 4 cycles of N+I. The primary endpoint was the proportion of subjects who had >10% tumor size reduction. Subjects were considered evaluable if they received 2 cycles of N+I and the first imaging evaluation. Subjects will proceed to curative surgery if feasible; otherwise, they will receive other treatment according to guidelines. Results: From Feb. 2019 to Mar. 2022, 43 subjects were enrolled (men/women 37/6, median age 64 years, HBsAg+/anti-HCV+ 26/5, BCLC stage A/B/C 4/13/26, median tumor size 8.7 cm (range 1.8-16.3), median alpha-fetoprotein 97.1 ng/mL (range 0.9-303000). Three subjects had early progression after 1 cycle of N+I. In the 40 evaluable subjects, 16 (40%) had >10% tumor size reduction, and 3 had downstage by BCLC. Twenty-four subjects received surgery and 8 (33%) had major pathological response (>90% tumor necrosis). As of July 15, 2022, the estimated 2-year PFS and OS were 47.1% (95% CI, 28.7-65.4) and 72.0% (95% CI, 56.0-88.1). The most common all-grade adverse event (AE) is hepatitis in 22 (51%). Grade 3-4 AE occurred to 19 subjects (most commonly hepatitis in 12), 14 of which were considered immune-related AE and required steroid. Conclusion: Neoadjuvant N+I is feasible for patients with potentially resectable HCC. Long-term follow-up is needed to clarify its efficacy in terms of reducing recurrence and improving survival.
    日期: 2023-11
    關聯: Annals of Oncology. 2023 Nov;34(Suppl. 3):S1390.
    Link to: http://dx.doi.org/10.1016/j.annonc.2023.09.140
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001106690100114
    顯示於類別:[蘇勇曄] 會議論文/會議摘要
    [陳立宗] 會議論文/會議摘要
    [蕭金福] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI001106690100114.pdf96KbAdobe PDF79檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋